NASDAQ:XERS - Xeris Pharmaceuticals Stock Price, Forecast & News

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

Xeris Pharmaceuticals Inc (NASDAQ:XERS) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($1.22) EPS for the quarter, topping the Zacks' consensus estimate of ($1.23) by $0.01. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.20 million. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. View Xeris Pharmaceuticals' Earnings History.

Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xeris Pharmaceuticals.

3 brokerages have issued twelve-month price objectives for Xeris Pharmaceuticals' shares. Their forecasts range from $12.00 to $18.00. On average, they expect Xeris Pharmaceuticals' stock price to reach $16.00 in the next year. This suggests a possible upside of 295.1% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.

News coverage about XERS stock has trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Xeris Pharmaceuticals.

Some companies that are related to Xeris Pharmaceuticals include Satsuma Pharmaceuticals (STSA), BioDelivery Sciences International (BDSI), Magenta Therapeutics (MGTA), Sinovac Biotech (SVA), Beyondspring (BYSI), BioSpecifics Technologies (BSTC), Innate Pharma (IPHYF), Progenics Pharmaceuticals (PGNX), Organogenesis (ORGO), Mallinckrodt (MNK), Mersana Therapeutics (MRSN), Cue Biopharma (CUE), AnaptysBio (ANAB), Merus (MRUS) and Aptorum Group (APM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Amarin (AMRN), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Agile Therapeutics (AGRX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Five Prime Therapeutics (FPRX), Heron Therapeutics (HRTX), Kala Pharmaceuticals (KALA) and Omeros (OMER).

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Citigroup Inc. (8.15%), ArrowMark Colorado Holdings LLC (7.14%), State Street Corp (1.85%), Blackstone Group Inc (1.67%), Geode Capital Management LLC (1.31%) and IHT Wealth Management LLC (0.34%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals.

XERS stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Goldman Sachs Group Inc. and Bank of America Corp DE. View Insider Buying and Selling for Xeris Pharmaceuticals.

XERS stock was bought by a variety of institutional investors in the last quarter, including Citigroup Inc., Blackstone Group Inc, ArrowMark Colorado Holdings LLC, California Public Employees Retirement System, State Street Corp, IHT Wealth Management LLC, Marshall Wace LLP and Marshall Wace North America L.P.. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals.

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XERS stock can currently be purchased for approximately $4.05.

Xeris Pharmaceuticals has a market capitalization of $109.33 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals.

The official website for Xeris Pharmaceuticals is http://www.xerispharma.com/.

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]